1. Progress in Biosensors for the Point-of-Care Diagnosis of COVID-19
   Miroslav Pohanka, 2022, Sensors CrossRef
2. Nano-Carriers of COVID-19 Vaccines: The Main Pillars of Efficacy
   Carolina Constantin et al, 2021, Nanomedicine CrossRef
3. Comparison of the Immune Response in Vaccinated People Positive and Negative to SARS-CoV-2 Employing FTIR Spectroscopy
   Gustavo Jesus Vazquez-Zapien et al, 2022, Cells CrossRef
4. Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study
   Nasamon Wanlapakorn et al, 2022, Human Vaccines & Immunotherapeutics CrossRef
5. Unilateral Axillary Lymphadenopathy in Cancer Patients Post-COVID-19 Vaccination: Review and Case Series
   Sumaya Hasan Zoughbor et al, 2023, Case Reports in Oncology CrossRef
6. COVID-19 Vaccines and Public Anxiety: Antibody Tests May Be Widely Accepted
   Leyuan Liu et al, 2022, Frontiers in Public Health CrossRef
7. Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines
   Naif Khalaf Alharbi et al, 2022, Infection and Drug Resistance CrossRef
8. Long-Term Antibody Response and Vaccination Efficacy in Patients with COVID-19: A Single Center One-Year Prospective Study from the Czech Republic
   Miroslav Fajfr et al, 2022, Viruses CrossRef
9. Long-term systemic and mucosal SARS-CoV-2 IgA response and its association with persistent smell and taste disorders
   Jessica Denis et al, 2023, Frontiers in Immunology CrossRef
10. Immediate Adverse Reaction and SARS-CoV-2 Anti-Spike Receptor Binding Domain IgG of COVID-19 Vaccines Among Health Staffs
    Waleed S. Rasheed et al, 2024, Disaster Medicine and Public Health Preparedness CrossRef
11. Testing Antigens, Antibodies, and Immune Cells in COVID-19 as a Public Health Topic—Experience and Outlines
    Monica Neagu et al, 2021, International Journal of Environmental Research and Public Health CrossRef
12. A study of SARS-CoV-2 delta variant breakthrough infections and side effects of the Oxford-AstraZeneca vaccine
    Nawfal R. Hussein et al, 2022, Public Health in Practice CrossRef
13. Significance of Anti-COVID-IgA antibody response in COVID-19 breakthrough infection in vaccinated patients – a single-centered study from Pakistan
    Sabiha Anis et al, 2023, Immunologic Research CrossRef
14. Association between Immunoglobulin G Levels and Adverse Effects Following Vaccination with the BNT162b2 Vaccine among Japanese Healthcare Workers
    Jun Otani et al, 2021, Vaccines CrossRef
15. Twelve-Month Longitudinal Serology in SARS-CoV-2 Naïve and Experienced Vaccine Recipients and Unvaccinated COVID-19-Infected Individuals
    Zion Congrave-Wilson et al, 2022, Vaccines CrossRef
16. Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan
    Chun-Min Kang et al, 2022, Journal of Clinical Virology CrossRef
17. Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
    Sabina Zurac et al, 2022, Scientific Reports CrossRef
18. Binding and Avidity Signatures of Polyclonal Sera From Individuals With Different Exposure Histories to Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Vaccination, and Omicron Breakthrough Infections
    Gagandeep Singh et al, 2023, The Journal of Infectious Diseases CrossRef
19. Dynamic observation of SARS‐CoV‐2 IgM, IgG, and neutralizing antibodies in the development of population immunity through COVID‐19 vaccination
    Ruiwei Jiang et al, 2022, Journal of Clinical Laboratory Analysis CrossRef
20. Determinants of COVID-19 Knowledge, Perception and Attitudes in Indonesia: A Cross-Sectional Survey
    Al Asyary et al, 2023, International Journal of Environmental Research and Public Health CrossRef
21. Intensity of Humoral Immune Responses, Adverse Reactions, and Post-Vaccination Morbidity after Adenovirus Vector-Based and mRNA Anti-COVID-19 Vaccines
    Ioanna Voulgaridi et al, 2022, Vaccines CrossRef
22. Kinetics and persistence of cellular and humoral immune responses to SARS‐CoV‐2 vaccine in healthcare workers with or without prior COVID‐19
    Mihaela Chivu‐Economescu et al, 2022, Journal of Cellular and Molecular Medicine CrossRef
23. SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response
    Yuki Takamatsu et al, 2022, Microbiology Spectrum CrossRef
24. Guardians of the oral and nasopharyngeal galaxy: IgA and protection against SARS‐CoV‐2 infection*
    Salma Sheikh‐Mohamed et al, 2022, Immunological Reviews CrossRef
25. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection
    Jeffrey L. Americo et al, 2022, Proceedings of the National Academy of Sciences CrossRef
26. Anti-SARS-Cov-2 S-RBD IgG Formed after BNT162b2 Vaccination Can Bind C1q and Activate Complement
    Anas H. A. Abu-Humaidan et al, 2022, Journal of Immunology Research CrossRef